通过作为调节miR489-3p/ARD1的CeRNA,LRRC75A-AS1促进乳腺癌细胞的增殖和侵入
Chunjiao Yu1,2, Zhiyuan Wang3, Xi Zhang4
1Institute of Biomedical Engineering, Kunming Medical University, 1168 West Chunrong Road, Chenggong District, Kunming, 650500, Yunnan, P.R. China.
Scientific reports
|August 26, 2025
概括
长非编码RNA LRRC75A-AS1 通过调节ARD1 的miR-489-3p来促进乳腺癌. 这种LRRC75A-AS1/ miR-489-3p/ ARD1通路驱动癌症的进展,并提供潜在的治疗点.
科学领域:
- 分子生物学
- 癌症学
- 遗传学
背景情况:
- 乳腺癌 (BC) 的进展涉及复杂的分子机制.
- 确定新的调节途径对于有效的治疗策略至关重要.
研究的目的:
- 阐明ARD1在乳腺癌进展中的分子机制.
- 研究LRRC75A-AS1/miR-489-3p轴在调节ARD1表达和BC恶性瘤中的作用.
主要方法:
- 定量逆转录聚合酶链反应 (RT-PCR) 用于基因表达分析.
- 双露西法酶报告测试,RNA免疫沉 (RIP) 和RNA拉下测试以验证分子相互作用.
- 在实验室测试 (殖民地形成,Transwell,Western blot) 和体内瘤异种移植实验,以评估功能作用.
主要成果:
- ARD1促进BC细胞的增殖,侵袭和上皮细胞转化为介质细胞 (EMT).
- LRRC75A-AS1 作为竞争的内源性RNA (ceRNA) 进行miR-489-3p,从而导致ARD1的上调.
- 在体内抑制LRRC75A- AS1的瘤生长,验证了LRRC75A- AS1/ miR-489-3p/ ARD1轴在BC进展中的作用.
结论:
- LRRC75A-AS1通过抑制miR-489-3p和上调ARD1促进乳腺癌的进展.
- LRRC75A-AS1/miR-489-3p/ARD1 ceRNA轴是BC的一个新调节途径.
- 这一轴代表了乳腺癌治疗的有前途的治疗目标.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K


